CA2710841C - Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof - Google Patents

Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof Download PDF

Info

Publication number
CA2710841C
CA2710841C CA2710841A CA2710841A CA2710841C CA 2710841 C CA2710841 C CA 2710841C CA 2710841 A CA2710841 A CA 2710841A CA 2710841 A CA2710841 A CA 2710841A CA 2710841 C CA2710841 C CA 2710841C
Authority
CA
Canada
Prior art keywords
csf
shaped
ypeg
peg
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2710841A
Other languages
English (en)
French (fr)
Other versions
CA2710841A1 (en
Inventor
Shiyuan Wang
Jianhua Zheng
Li Sun
Huili Cai
Meihua Yang
Yan He
Ping Chen
Hongyuan Deng
Liping Zhong
Shuying Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosteed Gene Expression Tech Co Ltd
Original Assignee
Biosteed Gene Expression Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosteed Gene Expression Tech Co Ltd filed Critical Biosteed Gene Expression Tech Co Ltd
Publication of CA2710841A1 publication Critical patent/CA2710841A1/en
Application granted granted Critical
Publication of CA2710841C publication Critical patent/CA2710841C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2710841A 2007-12-29 2007-12-29 Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof Active CA2710841C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/003897 WO2009086656A1 (zh) 2007-12-29 2007-12-29 Y型聚乙二醇修饰的g-csf及其制备方法和应用

Publications (2)

Publication Number Publication Date
CA2710841A1 CA2710841A1 (en) 2009-07-16
CA2710841C true CA2710841C (en) 2018-01-23

Family

ID=40852740

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2710841A Active CA2710841C (en) 2007-12-29 2007-12-29 Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof

Country Status (8)

Country Link
US (1) US8530417B2 (https=)
EP (1) EP2236521A4 (https=)
JP (1) JP2011507913A (https=)
CN (1) CN101627056B (https=)
AU (1) AU2007363326B2 (https=)
BR (1) BRPI0722341A2 (https=)
CA (1) CA2710841C (https=)
WO (1) WO2009086656A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101627056B (zh) 2007-12-29 2013-05-15 厦门伯赛基因转录技术有限公司 Y型聚乙二醇修饰的g-csf及其制备方法和应用
US9840546B2 (en) * 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
US20120226774A1 (en) 2011-02-23 2012-09-06 Apple Inc. Display snooping
ES2657870T3 (es) * 2012-03-01 2018-03-07 Alcare Co., Ltd. Apósito para heridas
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
CN106146325B (zh) * 2015-04-24 2019-01-29 北京键凯科技股份有限公司 一种y型多缩乙二醇衍生物及其制备方法
CN107446908A (zh) * 2016-06-01 2017-12-08 湖南华腾制药有限公司 分支型聚乙二醇修饰的l‑门冬酰胺酶及其制备方法
CN108525002B (zh) * 2017-03-01 2020-09-29 中国科学院化学研究所 一种具有高强粘附性能的可注射生物胶水及其制备方法与应用
CN114853872B (zh) * 2022-04-27 2023-11-17 山东新时代药业有限公司 一种聚乙二醇修饰rhG-CSF的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2223401A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Branched polyalkylene glycols
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
JP2003248136A (ja) * 2002-02-25 2003-09-05 Kyoei Senzai Kk 光ファイバ用複合フェルール及び光ファイバ接続用コネクタ
ES2291620T3 (es) * 2002-03-13 2008-03-01 Beijing Jiankai Technology Co., Ltd. Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior.
CN1778821A (zh) 2004-10-15 2006-05-31 北京凯正生物工程发展有限责任公司 化学修饰的粒细胞集落刺激因子偶联物及其制备方法
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
MX2008001706A (es) * 2005-08-04 2008-04-07 Nektar Therapeutics Al Corp Conjugados de una porcion g-csf y un polimero.
CN101627056B (zh) 2007-12-29 2013-05-15 厦门伯赛基因转录技术有限公司 Y型聚乙二醇修饰的g-csf及其制备方法和应用
WO2012064867A1 (en) * 2010-11-09 2012-05-18 Nektar Therapeutics Pharmacologically active polymer-g-csf conjugates

Also Published As

Publication number Publication date
EP2236521A4 (en) 2013-07-10
WO2009086656A1 (zh) 2009-07-16
BRPI0722341A2 (pt) 2014-03-18
AU2007363326B2 (en) 2014-01-30
US20110280826A1 (en) 2011-11-17
CN101627056A (zh) 2010-01-13
US8530417B2 (en) 2013-09-10
EP2236521A1 (en) 2010-10-06
AU2007363326A1 (en) 2009-07-16
JP2011507913A (ja) 2011-03-10
CN101627056B (zh) 2013-05-15
CA2710841A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
CA2710841C (en) Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof
US5359030A (en) Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
KR100961859B1 (ko) 지-씨에스에프 접합체
KR100773323B1 (ko) 지-씨에스에프 접합체
JP3177449B2 (ja) 水溶性ポリマーで修飾したコンセンサスインターフェロン
JP5419689B2 (ja) 顆粒球コロニー刺激因子の誘導体化
AU698944B2 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
KR101502645B1 (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ｂ, 이의 제조 방법 및 용도
US20130287733A1 (en) Interferon alpha mutant and its polyethylene glycol derivative
CN101389354A (zh) 用于与蛋白质和肽缀合的四个支链的树枝状大分子peg
JP2515389B2 (ja) ス―パ―オキサイドディスムタ―ゼ結合体
ES2386575T3 (es) Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
JP5458416B2 (ja) 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
JP2008543304A (ja) ヒト顆粒球コロニー刺激因子イソ型（ＨｕｍａｎＧｒａｎｕｌｏｃｙｔｅ−ＣｏｌｏｎｙＳｔｉｍｕｌａｔｉｎｇＦａｃｔｏｒＩｓｏｆｏｒｍｓ）
CN101671390B (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN108265044B (zh) 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN104447981B (zh) 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物
CN101385858B (zh) 纯化的peg化人生长激素缀合物及其药物制剂

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241125

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241125

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251118